{"id":"https://openalex.org/W4404329641","doi":"https://doi.org/10.2337/9781580406666.case39","title":"Pembrolizumab and Diabetic Ketoacidosis","display_name":"Pembrolizumab and Diabetic Ketoacidosis","publication_year":2018,"publication_date":"2018-01-01","ids":{"openalex":"https://openalex.org/W4404329641","doi":"https://doi.org/10.2337/9781580406666.case39"},"language":"en","primary_location":{"id":"doi:10.2337/9781580406666.case39","doi":"https://doi.org/10.2337/9781580406666.case39","is_oa":false,"landing_page_url":"https://doi.org/10.2337/9781580406666.case39","pdf_url":null,"source":{"id":"https://openalex.org/S4306462804","display_name":"American Diabetes Association eBooks","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/P4310320274","host_organization_name":"American Diabetes Association","host_organization_lineage":["https://openalex.org/P4310320274"],"host_organization_lineage_names":["American Diabetes Association"],"type":"ebook platform"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Atypical Diabetes Pathopysiology Clinical Presentations and Treatment Options","raw_type":"book-chapter"},"volume":{"id":"https://openalex.org/W4297815154","display_name":"Atypical Diabetes Pathopysiology Clinical Presentations and Treatment Options"},"type":"book-chapter","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5034020009","display_name":"Francesca Cottini","orcid":"https://orcid.org/0000-0001-8676-7840","observed_orcids":["https://orcid.org/0000-0001-8676-7840"]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Francesca Cottini","raw_affiliation_strings":["1Department of Internal Medicine, Division of Endocrinology, Diabetes & Metabolism, The Ohio State University, Columbus, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Internal Medicine, Division of Endocrinology, Diabetes & Metabolism, The Ohio State University, Columbus, OH","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5007315645","display_name":"Kathleen Marie Dungan","orcid":"https://orcid.org/0000-0003-1289-1595","observed_orcids":["https://orcid.org/0000-0003-1289-1595"]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kathleen Dungan","raw_affiliation_strings":["1Department of Internal Medicine, Division of Endocrinology, Diabetes & Metabolism, The Ohio State University, Columbus, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Internal Medicine, Division of Endocrinology, Diabetes & Metabolism, The Ohio State University, Columbus, OH","institution_ids":["https://openalex.org/I52357470"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I52357470"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.65386485,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"300","last_page":"304"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.8838000297546387,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.8838000297546387,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.05660000070929527,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.010599999688565731,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":1.0},{"id":"https://openalex.org/keywords/diabetic-ketoacidosis","display_name":"diabetic ketoacidosis","score":0.9980000257492065},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.9430000185966492},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.7310000061988831},{"id":"https://openalex.org/keywords/type-1-diabetes","display_name":"type 1 diabetes","score":0.7639999985694885},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.5860000252723694}],"concepts":[{"id":"https://openalex.org/C2781283889","wikidata":"https://www.wikidata.org/wiki/Q1130148","display_name":"Diabetic ketoacidosis","level":3,"score":0.8139587640762329},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.757615327835083},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6373273134231567},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.38432008028030396},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.24545538425445557},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.21762040257453918},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.15325453877449036},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.0},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.2337/9781580406666.case39","doi":"https://doi.org/10.2337/9781580406666.case39","is_oa":false,"landing_page_url":"https://doi.org/10.2337/9781580406666.case39","pdf_url":null,"source":{"id":"https://openalex.org/S4306462804","display_name":"American Diabetes Association eBooks","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/P4310320274","host_organization_name":"American Diabetes Association","host_organization_lineage":["https://openalex.org/P4310320274"],"host_organization_lineage_names":["American Diabetes Association"],"type":"ebook platform"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Atypical Diabetes Pathopysiology Clinical Presentations and Treatment Options","raw_type":"book-chapter"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.8048999905586243,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":5,"referenced_works":["https://openalex.org/W1893566975","https://openalex.org/W2104430075","https://openalex.org/W2131950300","https://openalex.org/W2137631342","https://openalex.org/W2158840473"],"related_works":["https://openalex.org/W4243762955","https://openalex.org/W4404329557","https://openalex.org/W2593804068","https://openalex.org/W4236165303","https://openalex.org/W4404315186","https://openalex.org/W2414155535","https://openalex.org/W2478325290"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-10-10T09:11:00.788812","created_date":"2024-11-14T00:00:00"}